Condition 1: Multiple Sclerosis. Condition 2: Dysphagia. Multiple sclerosis Dysphagia
Conditions
Interventions
Intervention 1: Intervention group: pyridostigmine tablet. The duration of intervention is 3 weeks. For the first 4 days of the study, this group will have half a 60 mg tablet of pyridostigmine, three
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: A diagnosis of multiple sclerosis is made by a neurologist specialized in multiple sclerosis, based on the 2017 McDonald criteria, and the patient is receiving treatment for multiple sclerosis. After explaining the goals and methods of the study and all the sections of the informed consent form, the patient is willing towards participation and cooperation. The patient has a DYMUS score of at least 3, based on the persian version of the questionnaire.
Exclusion criteria
Exclusion criteria: Any comorbidity due to previous neurological disorders, e.g. previous cerebrovascular accidents. Other neurological disorders A history of relapse (if MS type is relapsing-remitting) in the previous 3 months. An Expanded Disability Status Scale (EDSS) score above 7.5. Currently being under treatment with pyridostigmine for any reasons. A history of hypersensitivity to anticholinesterase inhibitors or any of the compounds found in our placebo. The patient has mechanical obstruction in intestinal or urinary tract. The patient is currently pregnant or breastfeeding. Dysphagia caused by other disorders than MS. Having a decision to start any other treatment for dysphagia in time of the study, or having started in the last 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient's score based on the Persian version of DYMUS questionnaire. Timepoint: In the beginning of the study, and after 1 and 3 weeks of intervention. Method of measurement: Persian version of DYMUS questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient's score based on the Persian version of EAT-10 questionnaire. Timepoint: In the beginning of the study, and after 1 and 3 weeks of intervention. Method of measurement: Persian version of EAT-10 questionnaire.;Patient's score based on the Persian version of SWAL-QOL questionnaire. Timepoint: In the beginning of the study, and after 3 weeks of intervention. Method of measurement: Persian version of SWAL-QOL questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Hamidi
Tehran University of Medical Sciences
Outcome results
None listed